Bristol Myers Squibb - Company Information
Bristol-Myers Squibb Company discovers, develops, and delivers innovative medicines for patients with serious diseases, focusing on oncology, immunolo...Read more
Headquarters
Contact
Linkedin
Company Size10,000+
Stock SymbolBMY
Websitebms.com
TypePublic
Bristol Myers Squibb Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by 6sense, used by Bristol Myers Squibb
Intelex
EHS Management is a web-based software for environment, health, and safety that optimizes ...
Bristol Myers Squibb Employee Profiles
Are you looking for the decision-makers at Bristol Myers Squibb? Get their email address, phone numbers, and other details from Linkedin or any website. Install and uncover Bristol Myers Squibb’s employee details in less than 30 secs.
Sign-up for 6sense Revenue AI™ for Sales
To find emails, direct dials, and more for prospects across the web.
Sign Up TodayDownload the 6sense Chrome Extension to get verified contact data of Bristol Myers Squibb employees
Install Now
Bristol Myers Squibb News & Press Releases
Sales prospecting needs to be timely and appropriate for the person and organization you are contacting. Following the most recent company news, alerts, and updates about the leads you are currently working on is the simplest and most convenient way to stay on top of them. Here are Bristol Myers Squibb latest news, alerts and updates.
Bristol Myers Squibb to acquire RayzeBio for $4.1 billion in cash
American multinational pharmaceutical company Bristol Myers Squibb on Tuesday said it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business
31 Dec 2023
Bristol Myers Squibb to acquire Karuna Therapeutics for $14bn
Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of all outstanding shares of common stock of biopharmaceutical company Karuna Therapeutics for an equity value totalling $14bn in cash.
29 Dec 2023
Bristol Myers Squibb Invests $4.1B for Acquisition of RayzeBio to Shore Up Cancer Therapy Portfolio
Bristol Myers Squibb acquired RayzeBio for a staggering amount of $4.1 billion. The global biopharmaceutical company is investing to bolster its cancer therapy portfolio and business. Terms of the Agreement
27 Dec 2023
Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst
H.C. Wainwright analyst Raghuram Selvaraju downgraded Karuna Therapeutics, Inc. (NASDAQ:KRTX) to Neutral from Buy, raising the Price Target to $330 from $300.
26 Dec 2023
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. The acquisition price is more than a 100% premium over RayZeBio stock's closing price of $30.
26 Dec 2023
Bristol Myers to Acquire Karuna, a Neuroscience Drugmaker, for $14 Billion
Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna Therapeutics, which makes drugs to treat schizophrenia and Alzheimer’s, in an all-cash deal valued at $14 billion as it looks to strengthen its pipeline of neuroscience drugs.
22 Dec 2023
FAQs for Bristol Myers Squibb
Explore frequently asked questions about Bristol Myers Squibb’s business, including founding details, header quarters, information on technology stack, industry listing, and other details.
How many employees are working at Bristol Myers Squibb?
What industry is Bristol Myers Squibb in?
What is Bristol Myers Squibb's tech stack?
Where are Bristol Myers Squibb's headquarters?
Get instant access to B2B contact data across the web
Sign Up Today
